The American Journal of Medicine
Volume 121, Issue 7 , Pages 583-585 , July 2008

Evolution

  • Naasha J. Talati, MD
    • ,
  • Nadine G. Rouphael, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Nadine Rouphael, MD, Division of Infectious Diseases, Emory University School of Medicine, 69 Jesse Hill Jr Dr SE, Atlanta, GA 30303.

References 

  1. Zillikens D. BP180 as the common autoantigen in blistering diseases with different clinical phenotypes. Keio J Med. 2002;51:21–28
  2. Bickle K, Roark TR, Hsu S. Autoimmune bullous dermatoses: a review. Am Fam Physician. 2002;65:1861–1870
  3. Smith EP, Zone JJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. Dermatol Clin. 1993;11:511–526
  4. Husz S, Kiss M, Molnár K, et al. Development of a system for detection of circulating antibodies against hemidesmosomal proteins in patients with bullous pemphigoid. Arch Dermatol Res. 2000;292(5):217–224
  5. Michel B, Milner Y, David K. Preservation of tissue-fixed immunoglobulins in skin biopsies of patients with lupus erythematosus and bullous diseases–preliminary report. J Invest Dermatol. 1972;59:449–452
  6. Kuechle MK, Stegemeir E, Maynard B, et al. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol. 1994;30:187–192
  7. Shimanovich I, Rose C, Sitaru C, et al. Localized IgA disease induced by ampicillin/sulbactam. J Am Acad Dermatol. 2004;51:95–98
  8. Plunkett RW, Chiarello SE, Beutner EH. Linear IgA bullous dermatosis in one of two piroxicam-induced eruptions: a distinct direct immunofluorescence trend revealed by the literature. J Am Acad Dermatol. 2001;45:691–696
  9. Acostamadiedo JM, Perniciaro C, Rogers RS. Phenytoin-induced linear IgA bullous disease. J Am Acad Dermatol. 1998;38(2 pt 2):352–356
  10. Armstrong AW, Fazeli A, Yeh SW, et al. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J Cutan Pathol. 2004;31:393–397
  11. Neughebauer BI, Negron G, Pelton S, et al. Bullous skin disease: an unusual allergic reaction to vancomycin. Am J Med Sci. 2002;323:273–278
  12. Nousari HC, Kimyai-Asadi A, Caeiro JP, Anhalt GJ. Clinical demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin (Report of 2 cases and review of the literature). Medicine. 1999;78:1–8(Baltimore)
  13. Waldman MA, Black DR, Callen JP. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol. 2004;29:633–636
  14. Cauza K, Hinterhuber G, Sterniczky B, et al. Unusual clinical manifestation of linear IgA dermatosis: a report of two cases. J Am Acad Dermatol. 2004;51(2 Suppl):S112–S117
  15. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin diseases other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc. 2005;80:41–47

 Parwathi “Uma” Paniker, MD, Section Editor

PII: S0002-9343(08)00352-5

doi: 10.1016/j.amjmed.2008.04.007

The American Journal of Medicine
Volume 121, Issue 7 , Pages 583-585 , July 2008

Article Tools

* Image Usage & Resolution